AllDocs -> cancers

The Marie Keating Foundation has been established to provide cancer information and awareness free of charge to general public throughout Ireland. Our Units carry information on Breast, Testicular, Prostate, Bowel, Lung, Skin, Ovarian and Cervical cancer . Our service is provided through our registered Nurses on board the Units, leaflet information, teaching aids, presentations, exhibitions and seminars. The Marie Keating Foundation offers Medical and Nursing Scholarships. Our future projects include Marie Keating Foundation waiting rooms within Cancer Care Hospitals. As the Marie Keating Foundation is not government funded we depend on private and corporate donations. We at the Marie Keating Foundation would like to thank Breast Check, The Irish Cancer Society, Action Cancer Northern Ireland, Cancer Research UK and health care professionals specializing in cancer care ...

CR AN E G I L MO R E & AS SO CI A T ES , I N C . O V A R I A N C A N C E R S E P T E M B E R 2 0 0 5 Phone: 309-674-8786 Fax: 309-674-8776 Email: info@cranegilmore.com Peoria, Illinois 61601 C R A N E G I L M O R E & A S S O C I A T E S , I N C . Dr. Don Crane writes a monthly article for the Em- ployers Asso- ciation re- sponding to questions posed by their members re- garding health care September is National Prostate and Ovarian Cancer Awareness Month. Because of limitations on space this article is going to concentrate on ovarian cancer . First “ ovarian tumor” and “ ovarian cancer ” are not the same. Ovarian tumors are common and are usually benign. Ovarian cancers are rare. A friend of mine is an Ob/Gyn in a very ...

Ovarian Cancer 15 Women in Usdaw Talking about W o me n U s da w in Page 2 Introduction This leaflet is designed to raise awareness of ovarian cancer , the fourth most common cancer among women in the UK. There are about 6,800 new cases each year. A woman’s lifetime risk of developing it is 1 in 55. Page 3 What is ovarian cancer ? Ovarian cancer is cancer that arises in the ovaries, a pair of almond shaped glands that lie on each side of the uterus which is located in the pelvis. The ovaries produce eggs and the female hormones that are responsible for female body characteristics as well as regulating the menstrual cycle. Ovarian cancer occurs when the cells in the ovary become ...

For the treatment of relapsed ovarian cancer I will fight my relapsed ovarian cancer because I have options for today and tomorrow. A First Choice for a Second Chance Page 2 You have many options for fighting relapsed ovarian cancer . One of them is Hycamtin ® (topotecan HCl) . If you’re reading this brochure, either you or someone close to you has suffered a relapse of ovarian cancer . A relapse is the return of your cancer after an initial response to treatment. And while learning that your ovarian cancer has relapsed is disheartening, the good news is that women with relapsed ovarian cancer are living longer, in part because they have more options than ever before to attack their disease. This brochure is designed to help you understand relapsed ovarian cancer ...

a report by Dr Alan N Gordon Clinical Professor of Obstetrical Gynecology, University of Arizona School of Medicine Long-term Survival Advantage for Recurrent Ovarian Cancer Patients Receiving Pegylated Liposomal Doxorubicin B U S I N E S S B R I E F I N G : E U R O P E A N O N C O L O G Y R E V I E W 2 0 0 5 83 Pharmacological Therapy OVARIAN CANCER Ovarian cancer remains the leading cause of death from gynaecologic malignancies. Although endometrial cancer occurs more frequently, the vast majority of patients who develop this disease present with post-menopausal or other irregular bleeding problems and are usually diagnosed with early-stage disease and experience long survival. In contrast, the presenting signs and symptoms of ovarian cancer are non-specific and almost 75% of patients already have extensive abdominal disease ...

FOR IMMEDIATE RELEASE: CONTACT: April 14, 2005 Ginny Dunn 8:30 a.m. ET EntreMed, Inc. Associate Director Corporate Communications & Investor Relations (240) 864-2643 ENTREMED GRANTED FDA ORPHAN DRUG STATUS FOR PANZEM ® (2ME2) IN OVARIAN CANCER ROCKVILLE, MD – April 14, 2005 – EntreMed, Inc. (Nasdaq: ENMD) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the Company’s lead compound, 2-methoxyestradiol (2ME2 or Panzem ® ), for the treatment of ovarian cancer . The FDA accepted EntreMed’s 2ME2 application upon review of data from preclinical experiments and a Phase I clinical study, together with in vitro data demonstrating that 2ME2 has activity against a variety of ovarian carcinoma cell lines including those resistant to other chemotherapeutic ...

Where to Start Sources of Information on Ovarian Cancer Suggestions for resources when you begin to look for information about ovarian cancer . Prepared by the Ninon Bourque Patient Resource Library The Ottawa Hospital Regional Cancer Centre 501 Smyth Road, Ottawa, ON, K1H 8L6 613-737-7700 ext 70107 These resources are provided for information purposes only and are not intended as a substitute for medical care. Inclusion of a resource does not imply endorsement by The Ottawa Hospital. If you have any questions about your healthcare, please consult your healthcare provider. If you would like to have more information about this topic, please contact the Ninon Bourque Patient Resource Library at 613-737-7700 ext. 70107 or consumerhealth@ottawahospital.on.ca . Basic Information Ovarian cancer : what you need to know . 11 page booklet with information ...

Center for Environmental Health Studies (617) 482-9485 44 Farnsworth Street, Boston, MA 02210 http://www.jsi.com Ovarian Cancer and Exposure to Ionizing Radiation 1 Ovarian Cancer and Exposure to Ionizing Radiation Summary : There has been moderately strong evidence recorded of a possible connection between ovarian cancer and exposure to ionizing radiation. This possible connection is supported by evidence from studies conducted at Los Alamos National Laboratory and other studies of nuclear workers at other sites who have been exposed to ionizing radiation. The National Research Council’s has determined that there is evidence among atomic bomb survivors of ovarian cancer in connection with exposure to ionizing radiation. Ovarian cancers are designated as “specified” cancers under the Energy Employees Occupational Illness Compensation Program Act. Historically, ...

A FREE course to all ovarian cancer survivors, friends, family members and others who are interested in hearing from the leading experts in ovarian cancer research from around the country. These experts will share new information about ovarian cancer . Time for questions and answers will be provided. Saturday, July 9, 2005 12:00 p.m. – 1:00 p.m. Registration 1:00 p.m. – 6:00 p.m. Course Refreshments will be provided during the Break Baltimore Marriott Waterfront Hotel 700 Aliceanna Street Baltimore, Maryland 21202 Phone: (410) 385–3000 www.thegcf.org www.wcn.org 2005 2 0 0 5 Ovarian Cancer Survivors Course 2 0 0 5 Ovarian Cancer Survivors Course Sponsored by the Gynecologic Cancer Foundation In partnership with the Gynecologic Oncology Group ...

Contact: Katherine Hinds, Office of Public Affairs • Phone: 203.932.7246 • Fax: 203.931.6008 • UNH e-mail: khinds@newhaven.edu NEWS For release: Immediately 21 June 2005 UNH RESEARCH HELPS FIGHT OVARIAN CANCER AND LYME DISEASE Graduate research projects that focus on Lyme disease, HRT therapy & more, presented June 22 WEST HAVEN, CT — Several graduate research projects in the Cellular and Molecular Biology program will be the focus of a morning-long presentation on the UNH campus, Wednesday, June 22, 2005, from 9-noon in Bartels Hall, Meeting Room A&B. The projects were undertaken in the graduate program of the Cellular and Molecular Biology program, part of the College of Arts & Sciences. “At UNH, students undertake important, applied research,” says Daniel Nelson, Dean of the College of Arts & Sciences. “Our Cellular & Molecular Biology graduate ...

Dr Eric Pujade-Lauraine is the Head of the French GINECO Group devoted to clinical research in gynaecologic cancer . He is also the Head of the Medical Oncology Unit in the Department of Haematology- Medical Oncology at Hôpital Hôtel- Dieu in Paris, France. While receiving his medical degree from the University of Paris VI, he was an intern at Assistance Publique des Hôpitaux de Paris. He later earned his PhD from the University of Paris VI, where he is now a Professor of Medical Oncology. As well as serving on several advisory boards, Dr Pujade-Lauraine is also a member of the American Society of Clinical Oncology, the European Society for Medical Oncology, and the Gynecologic Cancer Intergroup. B U S I N E S S B R I E F I N G : E U R O P E A N P H A R M A C O T H E R A P Y 2 0 0 5 1 Reference Section a report by Drs Eric ...

To register for this FREE event, phone 020 7972 1518 email mb-gaic@dh.gsi.gov.uk fl y er design: suki@twist-media.com Breast & Ovarian Cancer : Genetics and Insurance Committee Public Meeting Tuesday 12 July 2005 Copthorne Tara Hotel, Scarsdale Place, Kensington, London W8 5SR Page 2 To register for this FREE event, phone 020 7972 1518 email mb-gaic@dh.gsi.gov.uk Breast & Ovarian Cancer : 09:30 Registration 10:00 Opening remarks Professor David Johns (GAIC Chairman) 10:10 What is a predictive genetic test and how does it work? Professor Dian Donnai (GAIC Member - University of Manchester) 10:30 Counselling people considering ...

NOCA launches public awareness campaign on ovarian cancer Toronto, Ont., June 1 - The National Ovarian Cancer Association (NOCA) is excited to announce the launch of a major North American advertising campaign aimed at raising awareness about symptoms, support and treatment of ovarian cancer . In 2004, 2,300 Canadian women were diagnosed with ovarian cancer and each year 1,500 die of the disease. The campaign—themed “Turn Up the Volume!”—was developed to encourage women and doctors to listen more closely to quiet symptoms that may represent ovarian cancer . These symptoms can include abdominal pain, unusual bloating, urgent urination, nausea, gas and indigestion. Although ovarian cancer is the most fatal gynecologic cancer , the chance for survival increases significantly if the disease is detected and treated early. Since there is no reliable screening test for ovarian ...

Corinne Boyer Chair 2002 Annual Report Page 1 of 4 2002 Annual Report Corinne Boyer Chair in Ovarian Cancer Research University of Ottawa The past year has been a whirlwind of activity for the University of Ottawa's Corinne Boyer Chair in Ovarian Cancer Research. This report summarizes the progression during the past year of ovarian cancer research in Canada and highlights some of the major events that contributed to increased awareness of ovarian cancer , and ovarian cancer research. Reflection upon the activities of this past year has been very rewarding, as you will see that awareness of ovarian cancer is improving dramatically, and the research discoveries reported in the past year bode exceptionally well for a future that holds better detection and treatment options for women with ovarian cancer . The Ovarian Cancer Community One of my greatest ...

Pharmacogenetics 2001, 11:635±638 Original article 0960-314X # 2001 Lippincott Williams & Wilkins Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives Ingo B. Runnebaum a,b , Shan Wang-Gohrke a , Danny Vesprini c , Rolf Kreienberg a , Henry Lynch d , Roxana Moslehi c , Parviz Ghadirian e , Barbara Weber f , Andrew K. Godwin g , Harvey Risch h , Judy Garber i , Caryn Lerman j , Olufunmilayo I. Olopade k , William D. Foulkes l , Beth Karlan m , Ellen Warner n , Barry Rosen o , Timothy Rebbeck f , Patricia ...

For personal use. Only reproduce with permission from The Lancet Publishing Group. ARTICLES THE LANCET • Vol 357 • May 12, 2001 1467 Summary Background In several case-control and prospective studies, tubal ligation has been associated with a decreased risk of invasive epithelial ovarian cancer . We aimed to assess the potential of tubal ligation in reducing the risk of ovarian cancer in women who carry predisposing mutations in the BRCA 1 or BRCA 2 genes. Methods We did a matched case-control study among women from Canada, the USA, and the UK who had undergone genetic testing and who carried a pathogenic mutation in BRCA 1 or BRCA 2. Cases were 232 women with a history of invasive ovarian cancer , and controls were 232 women without ovarian cancer , and who had both ovaries intact. Cases and controls were matched for year of birth, country of residence, and ...

Reproductive factors and ovarian cancer risk in Jewish BRCA1 and BRCA2 mutation carriers (United States) Francesmary Modugno 1, *, Roxana Moslehi 2 , Roberta B. Ness 1 , Deborah Brooks Nelson 3 , Steven Belle 1 , Jeffrey A. Kant 4 , James E. Wheeler 5 , Aimee Wonderlick 6 , David Fishman 6 , Beth Karlan 7 , Harvey Risch 8 , Daniel W. Cramer 9 , Marie-Pierre Dube 2 & Steven A. Narod 2 1 Department of Epidemiology, University of Pittsburgh, Pittsburgh, USA; 2 Centre for Research on Women’s Health, Women’s College Hospital, University of Toronto; 3 Department of Clinical Epidemiology, University of Pennsylvania; 4 Department ...

Cancer Incidence in a Population of Jewish Women at Risk of Ovarian Cancer By Alexander Liede, Beth Y. Karlan, Rae Lynn Baldwin, Lawrence D. Platt, Graciela Kuperstein, and Steven A. Narod Purpose: To evaluate the incidence and clinical char- acteristics of ovarian and other cancers in a cohort of women at risk of developing ovarian cancer . Patients and Methods: The Gilda Radner Ovarian Cancer Detection Program in Los Angeles, CA, was established in 1991 to study the efficacy of screening in the early detection of ovarian cancer . We present find- ings from a historical cohort of 290 Jewish women who were offered BRCA testing for three common founder mutations ( BRCA1 185delAG and 5382insC and BRCA2 6174delT). Results: In 10 years, 17 cancers were observed (1,111 per 100,000 per year), including six breast and eight ovarian or ...

ORIGINAL ARTICLE Cancer risk after hospital discharge diagnosis of benign ovarian cysts and endometriosis C HRISTER B ORGFELDT 1 AND E LLIKA A NDOLF 2 From the 1 Department of Obstetrics and Gynecology, University Hospital, Lund, and the 2 Division of Obstetrics and Gynecology, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden Acta Obstet Gynecol Scand 2004; 83: 395–400. # Acta Obstet Gynecol Scand 83 2004 Background. The aim was to evaluate whether patients with benign ovarian cysts, func- tional ovarian cysts, or endometriosis have an increased risk of developing gynecologic cancer . Methods. The Swedish Hospital Discharge Register was used to identify a cohort of women discharged from hospital with the diagnoses of ovarian cyst (n ¼ 42217), ...

Approximately one in 70 American women will develop ovarian cancer during her lifetime. In most instances, the cause is unknown, but for one in 10 women with ovarian cancer , an inherited predisposition may be involved. Genetic risk assessment for ovarian cancer should be considered if a woman: s Has been diagnosed with ovarian cancer and is of Ashkenazi Jewish descent s Has been diagnosed with ovarian cancer and another cancer , such as breast, pancreatic, melanoma, colon or stomach s Has family members with any of the above s Has male relatives with breast or prostate cancer An inherited predisposition to various cancers often occurs as part of a broader hereditary cancer syndrome. Several hereditary ovarian cancer syndromes have been described, including: s Hereditary ...

FERTILITY AND OVARIAN CANCER A study published in January 1993 in the American Journal of Epidemiology (136:1184-1203) suggested a possible association between infertile women using drugs for ovulation induction and ovarian cancer . The study failed to specify, among other important information, the fertility drugs used by affected women. Nevertheless, it generated a lot of media attention and also raised concerns particularly among infertility patients with regard to the safety of the medications commonly prescribed by their physicians. The purpose of this communication is to clarify some of the points in the study that render it severely flawed in its design and conclusions. First, the study based its conclusions on 13 patients with ovarian cancer , 12 who had taken fertility enhancing medications and 1 who had not. The 12 affected patients were the only patients with ovarian cancer who had taken these ...

8/08/2004Access Policy -l June 2004.doc 1 AUSTRALIAN OVARIAN CANCER STUDY Policies and Procedures for Access to Data and/or Biological Specimens Who can apply to use AOCS data and/or biospecimens? During the data and sample collection phase of the Program, it is anticipated that access to the AOCS resource will be restricted mainly to the DoD-funded projects. This is solely to ensure that the DoD funded projects can be completed in a timely fashion. The resource will thus be widely available to non-DoD funded projects following formal application and review by the AOCS Program Management Committee (Appendix 1) from July 2006. After this time, any investigator(s) working in cancer research may apply to use the resource. However projects that have the potential to benefit Australian women will receive priority. In the intervening period (ie until July 2006), a limited number of additional projects ...

Breast and Ovarian Cancer Susceptibility Genes HOW DO I KNOW IF I CARRY A CHANGED BRCA GENE? The information presented here is intended to diagnose health problems or to take the place of professional medical care. If you have persistent health prob lems or if you have further questions, please consult your health care provider. Answer "yes" or "no" to the statements below. You may have a higher chance of carrying a changed BRCA gene if you answer "yes" to one or more of the following: • You have a close relative with a positive test for changed BRCA genes. • You have had both invasive breast and ovarian cancer . • You have invasive breast or ovarian cancer and • You have one or more close relatives with invasive breast cancer (especially before age 50) and/or ovarian cancer . • You ...

76 www.SupportiveOncology.net T HE J OURNAL OF S UPPORTIVE O NCOLOGY O B S E R V A T I O N S Incidence of Ovarian Cancer Varies In Europe E urope has one of the highest inci- dence rates of ovarian cancer in the world, making it an important public health issue. A new, large-scale study of ovarian cancer trends found that while incidence of the disease is declining in most northern European countries, it is increasing in a few southern and eastern European countries. Researchers led by Freddie Bray of the International Agency for Research on Cancer in Lyon, France, studied trends of ovarian cancer incidence and mortality in 28 European countries from 1953 until 2000 in order to try and un- derstand the variation in trends among countries. They examined ...

154 www.SupportiveOncology.net T HE J OURNAL OF S UPPORTIVE O NCOLOGY Liposomal Doxorubicin Earns Full Approval for Treatment of Ovarian Cancer T he US Food and Drug Administra- tion (FDA) has granted full ap- proval to liposomal doxorubicin (Doxil) for the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum- based chemotherapy. As a result of the full approval, the product label for lipo- somal doxorubicin has been updated to include survival, time to disease progres- sion, and tumor response rate data from a randomized phase III clinical study. Underacceleratedapproval,liposomal doxorubicin was indicated for the treat- ment of metastatic ovarian cancer in pa- tients with disease that was refractory to both paclitaxel- and ...

research for a cure laboratory without walls National Foundation for Cancer Research Cancer FAQs about ovarian cancer Frequently Asked Questions about common cancers. Page 2 Cancer FAQs Why is ovarian cancer so deadly? Ovarian cancer accounts for more deaths in the United States than any other gynecologic cancer . Hidden symptoms and a lack of reliable early- detection tests are to blame. Over 70 percent of all women with ovarian cancer are not diagnosed until the disease has spread beyond the ovary. At this stage, the likelihood of living for five years after diagnosis is between 20 percent and 25 percent. By contrast, at least 90 percent of women who are fortunate enough to have their cancer diagnosed and treated early, when the cancer is still confined to one or both ovaries, will survive for five years ...

Ovarian Cancer ( Cancer of the Ovary) What are the ovaries? Women have two ovaries, one on either side of the uterus (womb) in the lower abdomen. Ovaries are small and round, each about the size of a walnut. The ovaries make eggs. In fertile women, each month an egg (ovum) is released from one of the ovaries. The egg passes down the fallopian tube into the uterus where it may be fertilised by a sperm. The ovaries also make hormones including the main 'female' hormones - oestrogen and progesterone. These hormones pass into the bloodstream and have various effects on other parts of the body including regulating the menstrual cycle and periods. What is cancer ? Cancer is a disease of the cells in the body. The body is made up from millions of tiny cells. There are many different types of cell in the body, and there are many different types of cancer which arise from different types ...

CASE NOTE 01HDC00389: Missed diagnosis of ovarian cancer Right to services of an appropriate standard – Reasonable care and skill – Compliance with professional standards – General practitioner – Missed diagnosis – Cancer – Ovarian – Gynaecology – Clinical examination – Record keeping – NZMA Code of Ethics – Right 4(1) – Right 4(2) A complaint was made by a consumer about the care she received from a general practitioner. The complaint was on the basis that the general practitioner did not adequately examine the consumer, did not diagnose ascites, and did not refer her for further tests or assessment. The facts were that the consumer visited the GP for her annual vaginal smear. The GP did not examine her abdomen for lumps. Two months later the consumer returned after noticing a lump in her abdomen, and for a prescription to treat recurrence of her reflux oesophagitis. The GP informed her that the lump, viewed ...

FY04 Ovarian Cancer Research Program Peer Reviewers Aldaz, Claudio M.D., Ph.D. Department of Carcinogenesis, UT MD Anderson Cancer Center Bast, Robert M.D. Translational Research, UT MD Anderson Cancer Center Beck, William Ph.D. Department of Biopharmaceutical Sciences, University of Illinois at Chicago Benbrook, Doris Ph.D. Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center Berek, Jonathan M.D. Gynecologic Oncology, UCLA School of Medicine Blasberg, Ronald M.D. Neurology & Radiology, Memorial Sloan-Kettering Cancer Center Bonavida, Benjamin Ph.D. Department of Microbiology and Immunology, University of California-LA School of Medicine Bremner, Theodore Ph.D. Department of Biology, Howard University ...